These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32998861)

  • 1. Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases.
    Kasherman L; Madariaga A; Rouzbahman M; Murphy K; Shultz D; Stockley T; Oza AM
    Int J Gynecol Cancer; 2021 Jan; 31(1):139-143. PubMed ID: 32998861
    [No Abstract]   [Full Text] [Related]  

  • 2. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
    Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA
    Cancer; 2016 Jun; 122(12):1844-52. PubMed ID: 27062051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance olaparib in advanced ovarian cancer.
    Burki TK
    Lancet Oncol; 2018 Dec; 19(12):e671. PubMed ID: 30509885
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors plough on.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356598
    [No Abstract]   [Full Text] [Related]  

  • 6. Olaparib, a new hope for ovarian cancer.
    Samoon Z; Jabbar AA
    Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
    Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E
    Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review.
    Borrelli EP; McGladrigan CG
    J Oncol Pharm Pract; 2020 Dec; 26(8):1977-1986. PubMed ID: 32659172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors in BRCA mutation-associated ovarian cancer.
    Clamp A; Jayson G
    Lancet Oncol; 2015 Jan; 16(1):10-2. PubMed ID: 25481790
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study.
    Cerda VR; Lu D; Scott M; Kim KH; Rimel BJ; Kamrava M
    Int J Gynecol Cancer; 2022 Feb; 32(2):153-158. PubMed ID: 34911701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
    Pietragalla A; Minucci A; Marchetti C; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2019 Nov; 29(9):1440-1445. PubMed ID: 31537621
    [No Abstract]   [Full Text] [Related]  

  • 17. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
    Cao Y; Chen H; Huang Y; Hu H
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1180. PubMed ID: 32721133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.